Applied Genetic Technologies (AGTC)

Applied Genetic Technologies Stock Analysis & Ratings

AGTC Stock Chart & Stats

Day’s Range$0.76 - $0.84
52-Week Range$0.58 - $4.65
Previous Close$0.75
Average Volume (3M)584.47K
Market Cap$42.09M
P/E Ratio-0.5
Next EarningsMay 27, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-1.53



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Applied Genetic Technologies’s price range in the past 12 months?
Applied Genetic Technologies lowest stock price was $0.58 and its highest was $4.65 in the past 12 months.
    What is Applied Genetic Technologies’s market cap?
    Applied Genetic Technologies’s market cap is $42.09M.
      What is Applied Genetic Technologies’s price target?
      The average price target for Applied Genetic Technologies is $13.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $24.00 ,the lowest forecast is $8.00. The average price target represents 1452.05% Increase from the current price of $0.838.
        What do analysts say about Applied Genetic Technologies?
        Applied Genetic Technologies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Applied Genetic Technologies’s upcoming earnings report date?
          Applied Genetic Technologies’s upcoming earnings report date is May 27, 2022 which is in 9 days.
            How were Applied Genetic Technologies’s earnings last quarter?
            Applied Genetic Technologies released its earnings results on Feb 14, 2022. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.058.
              Is Applied Genetic Technologies overvalued?
              According to Wall Street analysts Applied Genetic Technologies’s price is currently Undervalued.
                Does Applied Genetic Technologies pay dividends?
                Applied Genetic Technologies does not currently pay dividends.
                What is Applied Genetic Technologies’s EPS estimate?
                Applied Genetic Technologies’s EPS estimate is -$0.33.
                  How many shares outstanding does Applied Genetic Technologies have?
                  Applied Genetic Technologies has 50,250,000 shares outstanding.
                    What happened to Applied Genetic Technologies’s price movement after its last earnings report?
                    Applied Genetic Technologies reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went down -0.81%.
                      Which hedge fund is a major shareholder of Applied Genetic Technologies?
                      Among the largest hedge funds holding Applied Genetic Technologies’s share is Farallon Capital Management, L.L.C.. It holds Applied Genetic Technologies’s shares valued at N/A.


                        Applied Genetic Technologies Stock Analysis

                        The Applied Genetic Technologies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Applied Genetic Technologies

                        Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

                        Similar Stocks
                        Price & Change
                        Adverum Biotechnologies
                        Sanofi-Aventis Sa

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis